Patent · US Active

Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity

US9522938B2 · kind B2 · utility

0Cited by

2References

20Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Martin Wald · Hamburg, DE
Oliver Cromwell · Bad Nenndorf, DE
Andreas Nandy · Hamburg, DE
Helga Kahlert · Hamburg, DE
Bernhard WEBER · Hamburg, DE
Helmut Fiebig · Schwarzenbek, DE

Key dates

Filing date	Jan 2, 2014
Grant date	Dec 20, 2016
Priority date	—
Expiry date	Jan 2, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/55561
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.